Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-1: AXS-05 for Agitation in Alzheimer's Disease
NCT03226522Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in Alzheimer's disease (AD), sponsored by Axsome Therapeutics, Inc.. Started Jul 2017; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03226522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226522.